The Quantellect read.As of Nov 20, 2026, 5 active firms cover Cardiff Oncology Inc: 2 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $2.00 to $9.00 (about 4.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $5.67 sits 533% above the current $0.90. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.13 next quarter toward $-0.52 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Neutral
Strong Buy00%
Buy240%
Neutral360%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$5.67
+532.7% upside
Average target across 3 active firms as of Nov 20, 2026 vs $0.90 current
Highest Target$9.00
Average Target$5.67
Lowest Target$2.00
Detailed analyst forecasts for CRDF
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 20, 2026, 2 of 5 active firms rate CRDF a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CRDF EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.16 – $-0.09 · 2 analysts · -31% YoY
Next period, 2 analysts expect Cardiff Oncology Inc to earn $-0.13 a share (range $-0.16 – $-0.09), versus $-0.18 a year earlier. Full-year consensus is $-0.56, growing to $-0.52 the year after.
REVENUE · NEXT QUARTER
$87.5K
Range $0 – $200.0K · 2 analysts · +113% YoY
Revenue is expected to reach $87.5K (range $0 – $200.0K), +113.4% year-over-year. Full-year consensus is $360.7K, rising to $320.8K next year.
Top analysts covering Cardiff Oncology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRDF.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$9.00+904.8% to target
Overall win rate
42%
+ Follow
#2
Joseph Catanzaro
Piper Sandler · Rank #353
Buy
$10.00+1016.4% to target
Overall win rate
41%
+ Follow
#3
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$6.00+569.9% to target
Overall win rate
29%
+ Follow
#4
RL
Robert LeBoyer
Noble Financial
Buy
$12.00+1239.7% to target
Coverage
—
+ Follow
#5
KD
Kevin DeGeeter
Ladenburg Thalmann
Buy
$19.00+2021.2% to target
Coverage
—
+ Follow
CRDF stock forecast FAQ
What is CRDF's average 12-month price target?+
The 3 active firms with a live target average $5.67 for Cardiff Oncology Inc over the next 12 months, ranging from a $9.00 high to a $2.00 low, as of Nov 20, 2026.
Is CRDF stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 5 active firms as of Nov 20, 2026, 2 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CRDF?+
The Street-high target is $9.00 (HC Wainwright & Co.), and the Street-low is $2.00 (Craig-Hallum). The average of all 3 active-firm targets is $5.67.
How many active Wall Street firms cover CRDF?+
5 active firms have a recognized rating on Cardiff Oncology Inc as of Nov 20, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CRDF?+
Among analysts who currently cover CRDF, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #215). Their current call is Buy with a $9.00 target.
What is Cardiff Oncology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.16 – $-0.09) across 2 analysts. Full-year EPS is projected at $-0.56, rising to $-0.52 the following year.
How much revenue is Cardiff Oncology Inc expected to report next quarter?+
Consensus revenue is $87.5K (range $0 – $200.0K). Full-year revenue is projected at $360.7K, growing to $320.8K next year.
Have analysts been upgrading or downgrading CRDF lately?+
As of Nov 20, 2026, 2 of 5 active firms rate CRDF a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRDF calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.